Fluorine-18-fluorocyclopropylhexadecanoic acid

N/A

Report date: 2025/11/25 17:50:09

Base Information

Drug NameFluorine-18-fluorocyclopropylhexadecanoic acid

Drug Alias Nametrans-9-18F-Fluoro-3,4-methylenehepadecanoic acid18F-fluorocyclopropylhexadecanoic acidFluorocyclopropylhexadecanoic acid-F-18FCPHACardioPET +[7]

ClassificationSmall moleculesRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18F +[4]

Mechanisms of ActionPositron-emission tomography enhancers

TargetsNot applicable

Therapy Area/IndicationsCoronary Artery Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMassachusetts General Hospital Harvard Medical School

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFluoropharma Inc

Active IndicationsN/A

Inactive IndicationsCoronary Artery Disease

Other Information

ATC CodeN/A